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SUMMARY
Balance between cell growth and proliferation deter-
mines cell size homeostasis, but little is known about
how metabolic pathways are involved in the mainte-
nance of this balance. Here, we perform a screenwith
a library of clinically used drug molecules for their ef-
fects on cell size.We find that statins, inhibitors of the
mevalonate pathway, reduce cell proliferation and in-
crease cell size and cellular protein density in various
cell types, including primary human cells. Mevalo-
nate pathway effects on cell size and protein density
are mediated through geranylgeranylation of the
small GTPase RAB11, which is required for basal au-
tophagic flux. Our results identify the mevalonate
pathway as a metabolic regulator of autophagy and
expose a paradox in the regulation of cell size and
proteostasis, where inhibition of an anabolic
pathway can cause an increase in cell size and
cellular protein density.
INTRODUCTION
Cell size and cell proliferation are connected yet independently
regulated processes (Ginzberg et al., 2015; Lloyd, 2013). It is
well known that proliferating cells can increase their size by
reducing the rate of cell division, so that cells have prolonged
time to accumulate mass and increase cell size. Consistently,
cell size increases that are due to reduced division rate are usu-
ally much less than those obtained by a complete cell-cycle
block. Nonetheless, most treatments that inhibit cell-cycle pro-
gression do not increase size as they impact both growth and
cell-cycle progression (Bjo¨rklund et al., 2006; Hoose et al.,
2012). Another mechanism for how cell size may be regulated
is by modulation of growth rate (Ginzberg et al., 2015; Lloyd,
2013). The increase in protein synthesis by mTOR activation is
a prime example of this. Proliferation and growth rate are thus
normally balanced to maintain cell size homeostasis.
Most studies on cell size controlmeasure either volume/area or
the drymass of the cells, but rarely both, thus ignoring changes in
the cellular composition. The intracellular density is considered to
remain relatively constant in different-sizedproliferatingmamma-
lian cells (Feijo´ Delgado et al., 2013), although the enlargement of
mammalian chondrocytes is a physiologically relevant example
where intracellular density is reduced (Cooper et al., 2013).
Changes in intracellular density are likely to have major physio-
logical consequences due to altered diffusion rates, enzyme ki-
netics, and intracellular signaling (Dill et al., 2011; Moura˜o et al.,
2014). However, it is not known if protein/dry mass accumulation
is always accompanied by a corresponding cell volume increase
or how protein content and cell volume can be uncoupled, result-
ing in upregulationofmacromolecular density. Thus, understand-
ing how cellular composition changes when cell size is altered is
an important aspect of cell size research.
The mevalonate pathway is crucial for the structure and func-
tion of cellular membranes and for many membrane localised
proteins. The pathway is transcriptionally controlled by Sterol
regulatory element-binding protein 2 (SREBP2) and the main
role of the pathway is to convert mitochondria-derived acetyl co-
enzyme A to numerous metabolites, including cholesterol, ubi-
quinones, dolichols, as well as isoprenoids required for protein
prenylation, which makes the pathway critical for the function
and localization of Rho and Rab small GTPases. Modulation of
the mevalonate pathway activity has therapeutic applications in
diseases like cancer and hypercholesterolemia. For example,
the rate-limiting step in the pathway, 3-hydroxy-3-methylglu-
taryl-coenzymeA reductase (HMGCR), is an important therapeu-
tic target for the widely used cholesterol-lowering drugs, statins.
Most research on cell size has focused on regulation of cell
signaling, but how different metabolic pathways affect cell size
homeostasis has gainedmuch less attention. We previously iden-
tified the mevalonate pathway as a potential cell size regulator
(Miettinen et al., 2014). The mevalonate pathway also has been
suggested to regulate cell proliferation through various mecha-
nisms, including prenylation of Rho proteins and regulation of
mitosis (Deshpande and Schedl, 2005; Sorrentino et al., 2014;
Wang et al., 2014), but how the cell size effects of this pathway
are mediated is not known. Here we report that the mevalonate
pathway affects cell size and cellular protein density through auto-
phagy and proliferation and that geranylgeranylation of the small
GTPase RAB11 is a key mechanism mediating these effects.
RESULTS
A Screen of FDA-Approved Drugs Reveals a Cell
Size-Modifying Role for Statins
To identify mechanisms related to cell size control, we screened
786 FDA-approved drugs for their effects on cell size and prolif-
eration effects using flow cytometry. The screen was performed
in the Jurkat T lymphocyte cell line with three biological
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replicates at 25-mM drug concentration, which was diluted for
the drugs that reduced cell count below reasonable levels
(<20%of control cell counts, see the Supplemental Experimental
Procedures). Whereasmost drugs reduced cell count after 48 hr,
only a small fraction of the tested drugs modulated cell size (Fig-
ure 1A; Table S1). The top three cell size-reducing drugs were
mTOR inhibitors (rapamycin and two rapamycin analogs), which
are well-known regulators of cell growth, thus validating our
approach. To understand the mechanisms behind cell size-
increasing drugs, we investigated the top 25 hits. Most of these
hits were involved in DNA synthesis or DNA damage, which one
would expect to lead to cell-cycle arrest and concomitant cell
size increase. In addition, we found two inhibitors of the meval-
onate pathway, lovastatin and rosuvastatin. Identification of
mevalonate pathway inhibitors in this screen corroborated our
previous findings that HMGCR and SREBP2 inhibition increased
cell size (Miettinen et al., 2014). To further validate this, we
measured the dose-dependent cell size effects of seven different
statins. All statins, except the most hydrophilic and, therefore,
the least cell-permeant statin, pravastatin, increased Jurkat
cell size. However, highest statin concentrations reduced cell
size, most likely due to toxic effects (Figures 1B, S1A, and S2).
Statin-Induced Cell Size Increase Is Accompanied by
Reduced Proliferation and Increased Cellular Protein
Density
The increased cell size after statin treatment was always accom-
panied by reduced cell counts (Figure S2), suggesting that the
size increase could be due to reduced proliferation rather than
increased growth. Although statins have been associated with
cell-cycle effects (Keyomarsi et al., 1991; Parikh et al., 2010),
we did not observe substantial cell accumulation in any specific
cell-cycle phase, as determined by DNA content analysis
(Figure S1B).
To examine if statins could slow down proliferation by an over-
all lengthening of the cell cycle, we labeled Jurkat cells with
CellTrace FarRed stain (DDAO-SE), treated the cells with pita-
vastatin, and monitored dye dilution as a measure for cell prolif-
eration every 24 hr. While dye dilution was not affected 24 hr
after statin treatment, at later time points dye dilution, and thus
proliferation, was reduced (Figure 1C). In addition, a statin-
induced cell size increase was observed in the presence of
mTOR inhibition (Figure S1C), suggesting that the mechanism
for how statins induce cell size is distinct from mTOR activity
modulation. Note that the cell size changes with statins are
similar in magnitude to those that can be obtained bymodulating
mTOR activity, the best-characterized pathway regulating cell
size (Figures 1A and S1C). Together with our previous observa-
tions (Miettinen et al., 2014), these data suggest that the statin-
treated cells proceed more slowly through the whole cell cycle,
which can explain the increased cell size.
To validate that the cell size increase also is reflected in an in-
crease in biomass, we labeled cellular proteins with amine-reac-
tive DDAO-SE, which robustly correlated with direct cell volume
measurements in untreated cells (R2 = 0.997, Figure S1D). These
data indicate that DDAO-SE is a valid measure of cellular
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Figure 1. High-Throughput Screen of 786
FDA-Approved Drugs Reveals Statins as
Cell Size-Modulating Compounds
(A) Relative cell size and count of Jurkat cells after
48-hr treatment with FDA-approved drugs are
shown (left, n = 3).
(B) Jurkat cell size effects after 72-hr treatment
with 2-fold increasing concentrations of statins.
Concentrations on the x axis are on a log2 scale
(n = 4). See Figure S2 for full details.
(C) Jurkat cell proliferation in the presence and
absence of pitavastatin (5 mM). The cells were
stainedwith CellTrace Far Red dye (DDAO-SE) and
the dye dilution, which reflects proliferation, was
measured every 24 hr from at least 50,000 cells.
The black histogram depicts the CellTrace dye
fluorescence distribution of the population before
treatment (starting point at 0 hr). The blue (DMSO)
and red (pitavastatin) histograms at various time
points (24–120 hr) display the fluorescent dye
dilution in the population due to cell division.
(D) Comparison of Jurkat cell protein densities af-
ter 72-hr statin treatments. Cellular protein content
was assessed by Bradford assay and DDAO-SE
protein labeling, while cell count and size were
analyzed by flow cytometry. Data are presented as
average protein density (protein content per cell
relative to cell size [FSC-A]). The slightly higher
increase in Bradford-based protein content mea-
surements is likely due to the protein from cell
debris, which is excluded in DDAO-SE-based flow
cytometer measurements. Note that these results
do not exclude the possibility that the density of
other cellular components also is increased.
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biomass, mainly protein (see the Supplemental Experimental
Procedures for discussion on the reactivity of cellular amines).
Unexpectedly, cells treated with statins displayed a much larger
increase in DDAO-SE signal compared to the cell volume in-
crease (Figures S1E and S1F), suggesting an increase in protein
density. We further validated this by measuring cellular protein
content using DDAO-SE labeling andBradford assay (Figure 1D).
This finding suggests that the mevalonate pathway differentially
affects cell volume and cellular protein content.
Statin-Induced Cell Size, Proliferation, and Protein
Density Effects Are Seen in Multiple Cell Types
Although all cell types maintain cell size homeostasis, mevalo-
nate pathway activity could differ among cell types and organ-
isms. We therefore tested whether statins could uncouple cell
size and proliferation in other cell models. Consistent with the
Jurkat cell data, human U2OS osteosarcoma cells treated with
statins displayed essentially no cell-cycle effects, despite clear
increases in cell size and especially cellular protein content (Fig-
ures S3A and S3B). The cell size effects of atorvastatin were not
observed when cell proliferation was blocked with gemcitabine-
induced S phase arrest (Figure S3C), suggesting that statins
affect the balance between growth (cell size increase) and prolif-
eration. In addition to human cells, the embryonic Drosophila
Kc167 cells increased in size and cellular protein density when
treated with statins (Figure S3D), suggesting that themechanism
for regulating cell size may be conserved. The Kc167 cells
also reduced their proliferation in the presence of mevalonate
pathway inhibition (Figure S3E), and the cell size effects
were independent of mTOR (data not shown). Immortalized
mouse embryonic fibroblasts (MEFs, Figure S4F) andprimary hu-
man umbilical vein endothelial cells (HUVECs) also were affected
by statins. HUVEC size and proliferation effects were observed
with submicromolar statin concentrations without changes to
the cell-cycle profile (Figures S3F and S3G). Together, these
data show that statins can increase cell size and reduce prolifer-
ation in several cell types and organisms, and these cell size in-
creases are accompanied by increased protein densities.
Systematic Mapping of the Mevalonate Pathway
Identifies Cell Size and Proliferation Effects as Being
Mediated through Geranylgeranylation
The mevalonate pathway branches to various biosynthetic
pathways. To understand the role of the mevalonate pathway
in controlling cell size, we systematically inhibited the pathway
in Jurkat and U2OS cells (see Figure 2A for pathway overview).
Chemical inhibition of Farnesyl Diphosphate Synthase (FDPS),
an enzyme downstream of HMGCR but upstream of most of
the mevalonate pathway branches, displayed cell size effects
comparable to statins (Figures 2B and S2). Targeting down-
stream branches of the mevalonate pathway for which chemical
inhibitors are available (Figure 2A) did not induce similar cell size
effects. Inhibition of Farnesyltransferase Beta (FNTB), required
for protein farnesylation, had no cell size effect, and inhibition
of Squalene Synthase (FDFT1), required for cholesterol synthe-
sis, or Protein Geranylgeranyltransferase (PGGT1B), required
for protein geranylgeranylation, caused only modest cell size
increases (Figures 2B, S2, and S4A).
Because small molecule inhibitors are not available for all
the branching pathways, we performed a small interfering RNA
(siRNA) screen using two independent siRNAs for each target
gene in U2OS cells (Figure 2A). Silencing of the early parts of
the mevalonate pathway displayed cell size increases as did
FDFT1 (Figure 2C). RNAi of Dehydrodolichyl Diphosphate
Synthase (DHDDS), required for protein N-glycosylation; Prenyl
(Decaprenyl) Diphosphate Synthase (PDSS1), required for ubi-
quinone synthesis; and the farnesyltransferase FNTB had no
cell size effect. However, inhibition of protein geranylgeranyla-
tion by RNAi silencing of PGGT1B and especially Rab Geranyl-
geranyltransferase (RABGGTA) induced large cell size changes
(Figure 2C), although chemical inhibition of PGGT1B was less
effective (Figure 2B). Consistent with these results and our pre-
vious observations (Miettinen et al., 2014), RNAi of SREBP2
increased cell size. These size effects took place in the absence
of cell-cycle effects and with concomitant cell count reductions
(Figure S4B; data not shown). Pairwise inhibition of separate
branches of the mevalonate pathway did not display any strong
synergy (Figure S4C).
To validate that geranylgeranylation is behind the statin-
induced cell size effects, we attempted to rescue the statin treat-
ments with downstream metabolites. In Jurkat cells, the cell size
and proliferation effects of statins were completely rescued
by mevalonate, indicating that the effects are specific for the me-
valonate pathway (Figure S4D). Cholesterol supplementation did
not rescue cell size, as was expected because Drosophila
cells are incapable of de novo cholesterol synthesis (Santos and
Lehmann, 2004). Supplementation with farnesylpyrophosphate
(FPP) rescued statin effects only partially (FigureS4D). In contrast,
geranylgeranylpyrophosphate (GGPP) rescued the cell sizes and
cell countscompletely (FigureS4D).Similar resultswere seen inall
our models (Figures S4E–S4G), including primary cells (HUVECs)
(Figure 2D). Furthermore, GGPP fully rescued the protein density
changes caused by mevalonate pathway inhibition (Figures 2D,
S4D, and S4E). These results indicate that mevalonate pathway
inhibitionmodulatescell size, cellular protein density, andprolifer-
ation mainly via protein geranylgeranylation. In addition, as the
relative expression of mevalonate pathway genes correlates
negatively with increased cell size in vivo (Miettinen et al., 2014),
it seems likely thatmevalonatepathwayactivity regulatescell size.
RAB11 GTPase Is Required for Cell Size Homeostasis
PGGT1BandRABGGTAare components of different geranylger-
anyltransferaseswith separate protein targets that require preny-
lation for their activity. As inhibition of the PGGT1 complex had
moremodest cell size effects than inhibition of theRABGGTcom-
plex (Figures 2B and 2C), we hypothesized that statin-induced
cell size and protein density effects are due to reduced Rab pro-
tein prenylation. While humans have over 60 Rab proteins (Welz
et al., 2014), Drosophila has only 33 (Zhang et al., 2007). Thus,
we generated and screened double-stranded RNAs (dsRNAs)
against the known Drosophila Rabs in Kc167 cells in order
to find Rab proteins affecting cell size. RNAi of Rab1 and
Rab11 displayed the largest effects onKc167 cell size (Figure 3A;
Table S2). However, validations with second independent
dsRNAs indicated that only Rab11 consistently regulated cell
size (Figure S5A). Rab11 directs recycling endosomes toward
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the cell surface, thus controlling the recycling of plasma mem-
brane components (Welz et al., 2014). This trafficking is depen-
dent on several Rab11-interacting proteins, includingDrosophila
Rip11 (Rab11-interacting protein) and Didum (Myosin V). Knock-
down of Rip11 and Didum also increased cell size in Kc167 cells
(Figure S5B). As with statin-induced cell size effects, Rab11 inhi-
bition by RNAi was accompanied by reduced proliferation (Fig-
ure S5C) and increased protein density (Figure S5D).
There are three RAB11 genes encoded in the human genome:
RAB11A, RAB11B, and RAB25. In U2OS cells, silencing of
RAB11 orthologs RAB11A and RAB11B robustly increased cell
size (Figure 3B). siRNAs targeting RAB1 and RAB25 did not
cause any cell size effects (Figures 3B and S5E). Curiously,
simultaneous inhibition of both RAB11A and RAB11B genes
did not result in additive cell size increase (Figure 3B), and it is
possible that single RAB11A or B knockdown could affect the
GTP- and/or membrane-bound status of the other RAB11 pro-
tein. We performed all subsequent RAB11 knockdowns with
combined siRNAs targeting both RAB11A and RAB11B.
In addition to in U2OS cells, silencing RAB11 also increased
cell size in HUVECs (Figure S5F). Aswithmevalonate pathway in-
hibition, RAB11 knockdown increased cellular protein density
(Figure 3C). We also silenced human RAB11-binding partners
MYO5B (Myosin Vb) and RAB11 family-interacting proteins
(FIPs) 1, 2, and 5, which are the human orthologs of Drosophila
Rip11. MYO5B- and FIP5-targeting siRNAs induced large cell
size changes in U2OS cells (Figures S5G and S5H). Furthermore,
overexpressing constitutively active (CA) RAB11Amutant (Q70A)
increased proliferation in U2OS cells (Figure S5I). Together these
results indicate that RAB11 and its binding partners involved in
vesicle trafficking can regulate cell size, protein density, and pro-
liferation in both human and Drosophila cells.
RAB11 Is a Mechanistic Link between the Mevalonate
Pathway and Cell Size
We next asked if inhibition of the mevalonate pathway could
mediate its cell size effects via RAB11. Inhibition of geranylgera-
nylation causes localization of Rab proteins from membranes to
cytosol. Indeed, similar concentrations of statins that increased
cell size also caused loss of membrane localization of RAB11
in U2OS cells (Figure S5J). As with cell size increase, RAB11
localization was much more sensitive to mevalonate pathway in-
hibition in HUVECs and was observed with submicromolar statin
concentrations (Figure 3D). We also validated the altered RAB11
localization with microscopy by expressing GFP-RAB11A in
U2OS cells. In control cells, RAB11 was mostly present in
vacuole-like structures at the perinuclear region, but 48-hr ator-
vastatin treatment caused RAB11 to localize throughout the
cytoplasm (Figure 3E). It has been shown before that statins
can have an impact on membrane localization of some Rab pro-
teins (Ostrowski et al., 2007). Consistently, RAB11 membrane
association is also lost after mevalonate pathway inhibition.
To investigate if RAB11mediates the cell size effects of meval-
onate pathway inhibition, we first combined RAB11 siRNAs with
statin treatments. Atorvastatin was not capable of increasing cell
size further after RAB11 was silenced in U2OS cells (Figure 3F),
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Figure 2. Geranylgeranylation Controls Cell Size and Proliferation
(A) Schematic illustration of the mevalonate pathway. Chemical inhibitors (red) and proteins targeted with siRNAs (blue) are indicated.
(B) Chemical inhibitions of the mevalonate pathway. Jurkat cell size effects after 72-hr treatment with 2-fold increasing concentrations of the indicated inhibitors
are shown. Concentrations on the x axis are on log2 scale (n = 4). See Figure S2 for full details.
(C) Genetic inhibitions of the mevalonate pathway. U2OS cell size effects after 72 hr with RNAi screen for the indicated targets are shown. Two independent
siRNAs were used for each gene. The statistical significances are from comparison to siRNA control samples (n = 3).
(D) HUVEC cell size and count and protein density changes after 72-hr treatment with rosuvastatin (7.5 mM) or atorvastatin (750 nM) and the indicatedmetabolites.
Protein density was measured with DDAO-SE labeling (relative to size). Data were normalized to each control for clarity (n = 4).
In (C) and (D), data are mean and SD.
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suggesting that the cell size effects of the mevalonate pathway
are at least partially mediated through RAB11. Similar results
were observed in MEFs (Figure S5K). We then overexpressed
wild-type and CA mutant RAB11A and concurrently treated the
cells with statins. CA RAB11 caused a partial rescue of statin-
induced cell size increase (Figure 3G), as would be expected
when the geranylgeranylation of RAB11 is not completely in-
hibited (Figure S5J). Together our results show that inhibition
of the mevalonate pathway increases cell size by a mechanism
that is at least partly mediated by reduced geranylgeranylation
and mislocalization of RAB11.
Mevalonate Pathway and RAB11 Are Required for Basal
Autophagic Flux
Our data indicated that statins increase intracellular protein con-
tent more than they increase cell size. Paradoxically, statins have
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(F) U2OS cell size effects after 72 hr with siRNA for RAB11 followed by atorvastatin treatment after the first 12 hr of RNAi. Two independent sets of siRNAs
targeting both RAB11 genes were used (n = 3).
(G) U2OS cells were transfected with wild-type (WT) or constitutively active (CA) RAB11a. After 12 hr, atorvastatin was added for 72 hr. Western blots on the
bottom show RAB11 levels after overexpression and siRNA knockdown targeting both RAB11 genes (n = 4).
Data in all panels are mean and SD. In (B) and (C), the statistical significances are from comparisons to control.
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been reported to inhibit protein production (Finlay et al., 2007)
and we also observed reduced protein synthesis rate in HUVECs
after treatment with atorvastatin, as measured by puromycin
incorporation (Figure S6A). We reasoned that the cellular protein
density increase is due to reduced protein breakdown. Statins
are considered to increase autophagy as high statin concentra-
tions increase autophagy markers in several cell culture models
(Ghavami et al., 2011, 2012; Parikh et al., 2010; Yang et al., 2010)
and in vivo (Ching et al., 2013; Yang et al., 2010; Zhang et al.,
2014). However, interpretation of autophagic flux from single
autophagy markers can be difficult and even misleading, as
the accumulation of autophagic structures may result from
increased induction of autophagy or inhibition of autophagy
due to failures in the autophagosome maturation (Ganley et al.,
2011; Klionsky et al., 2012; Mizushima et al., 2010). Rab proteins
are also important for autophagy as, for example, RAB11 con-
tributes to autophagosome formation (Longatti et al., 2012;
Puri et al., 2013) and fusion with other vesicular bodies (Fader
et al., 2008; Szatma´ri et al., 2014). We therefore hypothesized
that statins increase cellular protein content, at least partly, by in-
hibiting autophagy and thus causing the accumulation of excess
proteins.
We first tested if the mevalonate pathway can regulate auto-
phagosome formation. Consistent with previous studies, statins
induced the accumulation of autophagosomes, as measured by
CYTO-ID autophagy marker accumulation in Jurkat cells (Fig-
ure S6B). However, when we combined statins to inhibition of
autophagy, autophagosome accumulation was not increased,
as would be expected if statins increased autophagy (Fig-
ure S6B). The autophagosome accumulation was fully rescued
by GGPP. This suggested that protein geranylgeranylation is
required for autophagy under basal growth conditions. p62,
also known as Sequestosome 1, is an autophagy-selective sub-
strate that is constantly degraded by autophagy (Klionsky et al.,
2012; Mizushima et al., 2010). U2OS cells displayed an accumu-
lation of p62 in response to atorvastatin treatment and RAB11
RNAi (Figure 4A), indicative of an inhibition of autophagic flux.
Accumulation of p62 also was seen in HUVECs and could be
rescued with GGPP (Figure S6C). Statins and RAB11 RNAi
also increased LC3-II levels (Figure 4A), suggesting a late-state
inhibition of autophagy (Mizushima et al., 2010). The accumula-
tion of p62 was further increased by chloroquine, a lysosomal
inhibitor, suggesting that, while statins block autophagy, this in-
hibition may not be complete in HUVECs (Figure S6C).
Next we utilized RFP-GFP-LC3B tandem sensor, which labels
autophagosomes yellow and autolysosomes red, as the low
lysosomal pH quenches the GFP signal (Figure 4B, top left
corner). We validated this staining by microscopy (Figure 4B)
and quantified the RFP and GFP signals using flow cytometry.
In U2OS cells, atorvastatin increased RFP and GFP signals,
but caused a marked drop in the RFP/GFP ratio (Figures 4C
and S6D). Chloroquine induced a similar decrease in the RFP/
GFP ratio, but did not increase RFP or GFP signals as much as
atorvastatin. The atorvastatin-induced decrease in the RFP/
GFP ratio was dose dependent and could be largely rescued
with GGPP (Figure 4C), further indicating that protein geranylger-
anylation is required for normal autophagic flux. Similar results
were seen in HUVECs (data not shown).
To further validate that the mevalonate pathway is required for
basal autophagic flux, we inhibited SREBP2 with fatostatin, a
chemical inhibitor of SREBP processing, in HUVECs and U2OS
cells. Similar to HMGCR inhibitions, fatostatin caused accumula-
tions of p62 and LC3-II, both of which could be partly rescued by
mevalonate (Figure 4D). We also observed a modest accumula-
tion of p62 in response to SREBP2- and RABGGTA-targeting
siRNAs (Figure S6E). Then we used the RFP-GPF-LC3B sensor
to examine how fatostatin and SREBP2 siRNAs affect auto-
phagy. Both inhibitions clearly reduced the RFP/GFP ratio and
these changes were largely rescued by supplementation with
mevalonate (Figures 4E and 4F). We tested if inhibition of
RAB11 could explain the effects that mevalonate pathway inhibi-
tion causes on autophagy. Silencing RAB11 in U2OS cells
caused a similar decrease in the RFP/GFP ratio as mevalonate
pathway inhibition, and combining RAB11 siRNA and atorvasta-
tin did not display any additive effects in the RFP/GFP ratio (Fig-
ure 4G), suggesting that RAB11 and the mevalonate pathway
regulate autophagy through the same mechanism. These find-
ings do not exclude the possibility that statins may stimulate
autophagy initiation, as previously suggested. However, our re-
sults indicate that themevalonate pathway and geranylgeranyla-
tion of components like RAB11 are critical for normal function of
late stages of autophagy and, thus, for basal autophagic flux.
Mevalonate Pathway Is Not Required for Lysosomal
Functions
Autophagosomes fuse with lysosomes to degrade cytoplasmic
material. To exclude the possibility that the mevalonate pathway
causes a lysosomal defect rather than autophagy, we first
stained U2OS cells with LysoTracker Red dye, which accumu-
lates in acidic cell compartments. This displayed a marked in-
crease in the LysoTracker signal in response to mevalonate
pathway inhibition, which was largely rescued by the addition
of GGPP (Figures S7A and S7B). Similar results were seen
when the mevalonate pathway was inhibited using fatostatin
(Figure S7B). Thus, the mevalonate pathway is not required for
acidification or formation of lysosomes. We further examined
lysosomal activity using a fluorescent reporter of cathepsin B ac-
tivity. Similar to the LysoTracker signal, mevalonate pathway in-
hibition increased cathepsin B activity and this was fully rescued
by the addition of GGPP (Figure S7C).
To confirm that the increases in lysosomal content and activity
do not reflect increased autophagy, we compared wild-type and
Atg5-deficient MEFs (Kuma et al., 2004). Atg5 is an essential
component of the autophagosome elongation machinery and
knockout of Atg5 completely inhibits autophagy. We observed
that the LysoTracker signal was higher in the untreated Atg5-
deficient MEFs (Figure S7D). However, both the wild-type and
the Atg5-deficient MEFs displayed similar pattern of Lyso-
Tracker signal increase when the mevalonate pathway was in-
hibited (Figure S7E). As with U2OS cells, these effects were
largely rescued by supplementation with GGPP. Together, these
results indicate that inhibition of the mevalonate pathway in-
creases lysosomal activity but inhibits late stages of autophagy.
These results are consistent with previous reports suggesting
that Rab11 is required for the maturation of autophagosomes
in Drosophila (Szatma´ri et al., 2014).
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Mevalonate Pathway Modulates Proteostasis through
Autophagy
Bulk protein degradation by autophagy is critical for proteostasis
(Rubinsztein et al., 2012), and inhibition of autophagy by Atg7
deletion in mice results in hepatomegaly and cell size increase
(Komatsuet al., 2005).Nonetheless, the increasedcellularprotein
density caused by mevalonate pathway inhibition was unex-
pected. To further validate that the mevalonate pathway regu-
lates cellular protein density, we inhibited SREBP2 in U2OS cells
and observed increased cellular protein density, which was
largely rescued by supplementation with mevalonate (Figures
5A andS8A). Themevalonate pathway inhibitionwas not additive
to the effects caused by RAB11 RNAi in U2OS, Kc167, and MEF
cells (Figures 5B, S8B, and S8C), indicating that RAB11 is
involved in the mechanism regulating protein density. Next, we
combined various inhibitors of late autophagy and lysosomal ac-
tivity (chloroquine, pepstatin A, bafilomycin A1, and nocodazole)
(Klionsky et al., 2012; Rubinsztein et al., 2012) with mevalonate
pathway inhibition, for epistasis experiments in U2OS cells, to
examine if reduced protein degradation by autophagy could
cause the effects on cellular protein density. All the autophagy in-
hibitors increasedcellular proteindensity; however, thecombina-
tion of mevalonate pathway and autophagy inhibition displayed
no additive effects on protein density (Figure S7D). Similar results
were seen in Jurkat cells and HUVECs (Figures S8E and S8F).
Toconfirm that themevalonatepathwayeffects oncell sizeand
proteostasis are autophagy dependent, we compared wild-type
and Atg5-deficient MEFs. Statins induced dose-dependent cell
size and protein density increases in the wild-type MEFs, but
not in the Atg5-deficient MEFs (Figures 5C and 5D). Note that
the Atg5-deficient non-treated MEFs were already larger than
the wild-type cells and that the Atg5-deficient MEFs had a lower
protein density than thewild-typeMEFs, whichmay reflect differ-
ences between early (due to Atg5 deletion) and late-stage
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Figure 4. Mevalonate Pathway Is Required for Basal Autophagic Flux
(A) Western blot of U2OS cells treated with atorvastatin for 60 hr or siRNAs for 72 hr. GAPDH and Histone H3 were used as loading controls.
(B) Representative maximum-intensity projections from U2OS cells treated with the indicated chemicals and transfected with RFP-GFP-LC3B. Top left corner
displays a schematic illustration of the assay. Nuclei were stained with DAPI. Statin and GGPP (20 mM) were incubated with the cells for 72 hr, chloroquine for
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inhibition of autophagy (due to statins) or it may be an adaptation
to prolonged inhibition of autophagy. Next, we examined if
RAB11-induced cell size and protein density effects are auto-
phagy dependent. Silencing Rab11 increased cell size and pro-
tein density in wild-type MEFs, but not in the Atg5-deficient
MEFs (Figures 5E and 5F). The cell size effects caused by
RAB11 RNAi were similar to the cell size difference between
wild-type and Atg5-deficient MEFs. Altogether, the data indicate
thatmevalonate pathway andRAB11 effects on cell size and pro-
teostasis are mediated by autophagy. These results support our
findings that late stages of autophagy, most likely the maturation
of autophagosomes, are inhibited by the mevalonate pathway.
Finally, autophagy has a key role in the clearance of protein
aggregates from the cytoplasm (Rubinsztein et al., 2012), and
RAB11 has been shown to regulate the formation of
a-synuclein aggregates (Chutna et al., 2014). We thus tested
if mevalonate pathway-induced autophagy inhibition also af-
fects protein aggregation within the cells. We used the Proteo-
Stat reagent to stain protein aggregates, analyzed aggregate
accumulation with microscopy, and quantified the results
with flow cytometry. Atorvastatin treatment increased intracel-
lular protein aggregates in U2OS cells and this was rescued
by supplementation with GGPP (Figures 5G and 5H). Similar
results also were seen in Jurkat cells (data not shown). These
results indicate that the mevalonate pathway also regulates
protein aggregate accumulation, thus suggesting that mevalo-
nate pathway inhibition has profound consequences on
proteostasis.
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Figure 5. Inhibition of Autophagy Is Required for the Cell Size and Proteostasis Effects
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(G) Representative maximum-intensity projections of U2OS cells treated with the indicated chemicals and stained with ProteoStat reagent and DAPI. MG-132, a
proteasome inhibitor, was used as a positive control. Statin treatments were 72 hr and MG-132 treatments were 24 hr.
(H) Flow cytometry-based quantifications of intracellular protein aggregates from samples in (G) (n = 3–4). Note that protein aggregate measurement is inde-
pendent of the protein density measurements performed with DDAO-SE.
(I) Schematic of the proposed metabolic regulation of autophagy, cell size homeostasis, and cellular proteostasis. Proteins are displayed in blue, metabolites and
metabolic routes in orange, and complex cellular processes in black.
Data in all panels are mean and SD.
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DISCUSSION
Various aspects of cellular physiology are known to be controlled
by the mevalonate pathway due to its key role in cholesterol syn-
thesis as well as in protein prenylation of Rho GTPases (Finlay
et al., 2007; Sorrentino et al., 2014; Wang et al., 2014). Effects
causedby reducedgeranylgeranylationofRabproteins, however,
have gained less attention, possibly due to lack of methods for
rescuing reduced Rab protein geranylgeranylation. While we
cannot completely exclude contribution by other geranylgerany-
lated proteins, RAB11 appears to be largely responsible for the
cell size and proteostasis effects due to its role in autophagy.
Our results show that the mevalonate pathway regulates cell
size via protein geranylgeranylation, which is required for normal
autophagyandproliferation (Figure5I).However, it is alsopossible
that the inhibition of autophagy is responsible for the reduced
proliferation. A possible mechanism could be that autophagy-
mediated protein degradation is directly required for cell-cycle
progression and/or for generation of amino acids or other metab-
olites to support proliferation. The magnitude of the cell size
changes also varied between cell lines and mevalonate pathway
inhibitions. This may reflect the level of activity and/or depen-
dency of the cells on themevalonate pathway, as well as the level
of basal autophagy. Additionally, cell size effects obtained with
RNAiwere smaller than thoseseenwithchemical inhibitions, likely
reflecting the fact that small molecule inhibition is immediate
compared to the gradual decline in protein levels after RNAi.
Consistent with our results that the mevalonate pathway reg-
ulates cell size through proliferation and autophagy, it has
been shown that proliferation can be driven by protein geranyl-
geranylation (Freed-Pastor et al., 2012), that a mouse strain
with activity-reducing mutation in Rab geranylgeranyl trans-
ferase displays increased megakaryocyte size (Detter et al.,
2000), and that statins associate with reduced autophagic flux
in mice (Zhang et al., 2014). In addition, myosin Vb inhibition
has been shown to modify cell size in vivo and in primary cells
(Sonal et al., 2014; van Diepen et al., 2009), although these
studies disagree on the direction of size change. These reports,
together with our previous observations that the mevalonate
pathway is downregulated with increasing cell size in vivo (Miet-
tinen et al., 2014), suggest that our findings on cell size regulation
are physiologically relevant.
Unexpectedly, we found that inhibition of the mevalonate
pathway increases cellular protein content more than cell size.
Mechanistically, this increase in cellular protein densitywas regu-
lated through RAB11 and autophagy (Figure 5I). These effects on
proteostasismay require specific inhibition of late stages of auto-
phagy, as theAtg5-deficient cells, where autophagosome forma-
tion is inhibited, displayeda reducedprotein density. It is possible
that the increased protein density is partly due to the accumula-
tion of proteins in autophagosomes. However, RAB11 also con-
trols endosomal recycling, which is capable of regulating plasma
membrane amount (Boucrot and Kirchhausen, 2007). Therefore,
inhibition of RAB11 could reduce the availability of cell surface
components, thus impeding an increase in cell volumecompared
to intracellular protein accumulation. Such a constrained in-
crease in plasma membrane in the presence of continuous pro-
tein accumulation would result in increased macromolecular
crowding inside the cell, which also could explain the formation
of protein aggregates. Alternatively, growth factor receptors,
transferrin, and glucose transporters are known cargo trans-
ported by recycling endosomes (Welz et al., 2014). As all of these
are required for growth and proliferation, we cannot rule out the
possibility that perturbation of one or more of these components
could be involved in the observed phenotype.
Changes in proteostasis are well known to play key roles in
several neurodegenerative diseases (Frake et al., 2015), which
also are associated with Rab11 function (Richards et al., 2011)
and metabolic changes (Vazquez, 2013; Vazquez and Oltvai,
2011). Thus, modulation of autophagy and proteostasis may
explain some of the pleiotropic effects of statins. Consistent
with this, statin toxicity has been shown to be exacerbated by
further inhibition of autophagy (Ghavami et al., 2011, 2012;
Zhang et al., 2014), and it is possible that the inhibition of late
stages of autophagy and altered proteostasis are involved in
statin toxicity in a clinical setting.
Our results expose the paradoxical nature of cell size regula-
tion, where an inhibition of a biosynthetic process, in this case
the mevalonate pathway, can cause an increase in cell size.
What matters is the relative change in the ratio between the syn-
thetic and degradative rates and how these are coupled to cell
division. For example, growth factor signaling-induced cell size
is often accompanied by an increase in both biosynthesis and
degradation, but biosynthesis relatively more (Lloyd, 2013).
Our findings onmetabolic regulation of cell size and protein den-
sity indicate that increased cell size and protein density can be
achieved through reduced protein biosynthesis if there is an
even more pronounced reduction of protein degradation.
EXPERIMENTAL PROCEDURES
Cell Culture
Jurkat cells were cultured in RPMI media supplemented with 10% fetal bovine
serum (FBS), L-glutamine, and penicillin and streptomycin. U2OS and Kc167
cells were cultured as described previously (Miettinen and Bjo¨rklund, 2015).
HUVECs (Life Technologies, pooled from multiple donors) were cultured ac-
cording to the supplier’s recommendations in Medium 200 supplemented
with Low Serum Growth Supplement and gentamycin/amphotericin. Atg5-
deficient and control MEFs were cultured in DMEM supplemented with 10%
FBS, L-glutamine, and penicillin and streptomycin. HUVECs were used for
experiments between passages 4 and 13. All experiments were done before
cells reached confluence.
Chemical and Genetic Inhibitions and Protein Expression
Human siRNA (Integrated DNA Technologies) transfections were done as
described previously (Miettinen and Bjo¨rklund, 2014), with the exception of
HUVECs, which were transfected using Amaxa Nucleofector I (Lonza) accord-
ing to the supplier’s recommendations and co-transfected GFP as amarker for
transfected cells. Non-targeted NC1 siRNA (Integrated DNA Technologies)
was used as a control. Drosophila dsRNAs were prepared and used as before
(Miettinen et al., 2014). All siRNA treatments were 40 nM in total (20 + 20 nM
when combining two independent siRNAs), with the exceptions of HUVEC
cell experiments, where a total of 25 nM siRNAs was used, and MEF experi-
ments, where a total of 80 nM siRNAs was used. Mevalonate was supple-
mented to the cells as mevalolactone (Sigma-Aldrich). See Table S1 for
suppliers and solvents of all small molecule inhibitors and metabolites. See
Table S2 for details on siRNAs and dsRNAs.
For expression of wild-type human RAB11A, CA Q70A RAB11A, or GFP-
RAB11A, synthetic DNA constructs were cloned into cytomegalovirus pro-
moter-driven Gateway expression vector and transfected as in Miettinen
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and Bjo¨rklund (2014). The RFP-GFP-LC3B tandem sensor (Life Technologies)
was transfected using BacMam 2.0 expression technology according to the
supplier’s recommendations 24 hr before fixation and analysis.
Flow Cytometry
Cell sizes (mean FSC-A), cell counts, and fluorescence quantifications were
measured using a flow cytometer (Accuri C6, Becton Dickinson). For protein
measurements, cells were stained with 1 mM DDAO-SE (Life Technologies)
and the signal was normalized to FSC-A to obtain protein density. Note that
most cellular amines that are reactive with the DDAO-SE are in proteins, as
most amines in other biomolecules have pKa values above the physiological
pH, rendering them unreactive to DDAO-SE, and as most of the dry weight
of a cell is protein (60%). Protein content also was measured using Bradford
assays. DNA content wasmeasured using propidium iodide staining. Dye dilu-
tion-based proliferation assays were carried out by staining the cells with 2 mM
DDAO-SE, after which cells were cultured as before until analysis at the indi-
cated time points. Cytotoxicity was measured using CellTox Green Cytotox-
icity Assay (Promega). For quantification of autophagosomes, cells were
stained with CYTO-ID Green Autophagy detection reagent (Enzo Life Sci-
ences). The RFP-GFP-LC3B signals were detected from more than 10,000
live cells per replicate, cells with no signal above autofluorescence were
excluded, and signal ratios were used as an indicator of autophagic flux (Miz-
ushima et al., 2010). Lysosomal content was measured by staining the cells
with 50 nM LysoTracker Red dye (Life Technologies). Cathepsin B activity
wasmeasured using the Magic Red Cathepsin B Assay Kit (ImmunoChemistry
Technologies). Protein production was measured using Click-iT Plus OPP
Alexa Fluor 488 Protein Synthesis Assay Kit (Life Technologies). Cellular pro-
tein aggregate content was analyzed with ProteoStat Aggresome detection re-
agent (Enzo) from 4% paraformaldehyde-fixed cells. All fluorescence signals,
except those of DDAO-SE-based protein content measurements and RFP-
GFP-LC3B-based ratios, were normalized to cell size (FSC-A). See the Sup-
plemental Experimental Procedures for more details.
Statistical Analysis
Statistical significances were evaluated by ANOVA and two-tailed t test with
Holm-Sidak post hoc test to obtain multiplicity adjusted p values, using
SigmaPlot (ns, non-significant; *p < 0.05, **p < 0.01, and ***p < 0.001 in all
figures). All error bars represent mean and SD of biological replicates (n).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.11.045.
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